100 related articles for article (PubMed ID: 28453877)
21. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model.
Petersen SB; Nielsen FS; Ribel U; Sturis J; Skyggebjerg O
J Pharm Pharmacol; 2013 Feb; 65(2):230-5. PubMed ID: 23278690
[TBL] [Abstract][Full Text] [Related]
23. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
24. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
[TBL] [Abstract][Full Text] [Related]
25. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.
Garg S; Brazg RL; Bailey TS; Buckingham BA; Slover RH; Klonoff DC; Shin J; Welsh JB; Kaufman FR
Diabetes Technol Ther; 2012 Mar; 14(3):205-9. PubMed ID: 22316089
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation.
Haidar A; Duval C; Legault L; Rabasa-Lhoret R
J Diabetes Sci Technol; 2013 Nov; 7(6):1507-12. PubMed ID: 24351176
[TBL] [Abstract][Full Text] [Related]
27. Closed-Loop Control of Postprandial Glycemia Using an Insulin-on-Board Limitation Through Continuous Action on Glucose Target.
Rossetti P; Quirós C; Moscardó V; Comas A; Giménez M; Ampudia-Blasco FJ; León F; Montaser E; Conget I; Bondia J; Vehí J
Diabetes Technol Ther; 2017 Jun; 19(6):355-362. PubMed ID: 28459603
[TBL] [Abstract][Full Text] [Related]
28. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.
Cengiz E; Weinzimer SA; Sherr JL; Tichy EM; Carria L; Cappiello D; Steffen A; Tamborlane WV
Diabetes Technol Ther; 2014 Jan; 16(1):20-5. PubMed ID: 24367934
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
31. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.
Del Favero S; Place J; Kropff J; Messori M; Keith-Hynes P; Visentin R; Monaro M; Galasso S; Boscari F; Toffanin C; Di Palma F; Lanzola G; Scarpellini S; Farret A; Kovatchev B; Avogaro A; Bruttomesso D; Magni L; DeVries JH; Cobelli C; Renard E;
Diabetes Obes Metab; 2015 May; 17(5):468-76. PubMed ID: 25600304
[TBL] [Abstract][Full Text] [Related]
32. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
[TBL] [Abstract][Full Text] [Related]
33. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.
Vaughn DE; Muchmore DB
Endocr Pract; 2011; 17(6):914-21. PubMed ID: 22138081
[TBL] [Abstract][Full Text] [Related]
34. A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection.
Reutens AT; Balkau B; Cohen N
Diabetes Technol Ther; 2014 Apr; 16(4):235-40. PubMed ID: 24286115
[TBL] [Abstract][Full Text] [Related]
35. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.
Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
Diabetes Metab; 2016 Sep; 42(4):249-55. PubMed ID: 27068361
[TBL] [Abstract][Full Text] [Related]
36. Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
Nosek L; Cardot JM; Owens DR; Ibarra P; Bagate K; Vergnault G; Kaiser K; Fischer A; Heise T
Diabetes Obes Metab; 2012 Dec; 14(12):1137-44. PubMed ID: 22988932
[TBL] [Abstract][Full Text] [Related]
37. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
38. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
[TBL] [Abstract][Full Text] [Related]
39. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps.
Pickup JC
Diabetes Technol Ther; 2011 Jul; 13(7):695-8. PubMed ID: 21668344
[No Abstract] [Full Text] [Related]
40. Initial Basal and Bolus Rates and Basal Rate Variability During Pump Treatment in Children and Adolescents.
Demir G; Atik Altınok Y; Özen S; Darcan Ş; Gökşen D
J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):198-203. PubMed ID: 33374094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
